Glenmede Trust’s Acceleron Pharma XLRN Stock Holding History

Glenmede Trust’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-37	Closed	-$4K	–	2504
2020 Q3	$4K	Buy	37 +27	+270%	+$2.69K	﹤0.01%	2170
2020 Q2	$0	Buy	+10	New	+$964	﹤0.01%	2696
2019 Q2	–	Sell	-12,760	Closed	-$594	–	3231
2019 Q1	$594	Buy	+12,760	New	+$560K	﹤0.01%	853
2017 Q3	–	Sell	-13,186	Closed	-$349K	–	2883
2017 Q2	$349K	Hold	13,186	–	–	﹤0.01%	1032
2017 Q1	$349K	Hold	13,186	–	–	﹤0.01%	1032
2016 Q4	$336K	Buy	+13,186	New	+$418K	﹤0.01%	1052
2015 Q4	–	Sell	-18,548	Closed	-$461K	–	2809
2015 Q3	$461K	Hold	18,548	–	–	﹤0.01%	925
2015 Q2	$586K	Buy	18,548 +6,831	+58%	+$220K	﹤0.01%	885
2015 Q1	$445K	Hold	11,717	–	–	﹤0.01%	998
2014 Q4	$456K	Buy	11,717 +9,035	+337%	+$315K	﹤0.01%	995
2014 Q3	$81K	Hold	2,682	–	–	﹤0.01%	1544
2014 Q2	$91K	Buy	+2,682	New	+$89.7K	﹤0.01%	1441

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Glenmede Trust's XLRN Position: Q4 2020 in Review

Glenmede Trust sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 37 shares — an estimated $4K sold.

Glenmede Trust first reported a position in XLRN in Q2 2014 and held it in 12 quarters. The position peaked at $586K in Q2 2015. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

Glenmede Trust reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 37 Acceleron Pharma shares in Q4 2020, an estimated $4K.
Glenmede Trust first reported a position in Acceleron Pharma in Q2 2014 and held it in 12 quarters.
Glenmede Trust's Acceleron Pharma position peaked at $586K in Q2 2015.
253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.